China Invests RMB 200 Million In Engineering Research Center For New Vaccines
This article was originally published in PharmAsia News
Executive Summary
China National Biotec Group, China CDC's National Institute for Viral Disease Control and Prevention and two other biotech companies recently held a groundbreaking ceremony for their co-funded national engineering research center for new vaccines. With a total investment of over RMB 200 million ($29.3 million), the facility will feature five separate pilot platforms for inactivated viral vaccines, attenuated viral vaccines and bacterial vaccines. When completed by the end of next year, the center will apply modern biotechnology to improve conventional vaccines, tackle key technological problems in new vaccine R&D and commercialization, as well as focus on development and pilots of new vaccines, recombinant proteins, peptide drugs and nucleic acid drugs. (Click here for more - Chinese Language)